Compare CIVB & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CIVB | TECX |
|---|---|---|
| Founded | 1884 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 366.8M |
| IPO Year | N/A | 2018 |
| Metric | CIVB | TECX |
|---|---|---|
| Price | $22.95 | $20.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $25.40 | ★ $80.40 |
| AVG Volume (30 Days) | 84.4K | ★ 223.4K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ 33.31 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $163,095,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $11.12 | N/A |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | ★ 11.28 | N/A |
| 52 Week Low | $17.47 | $13.70 |
| 52 Week High | $25.59 | $61.07 |
| Indicator | CIVB | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 52.04 |
| Support Level | $22.27 | $17.77 |
| Resistance Level | $24.00 | $19.64 |
| Average True Range (ATR) | 0.66 | 1.37 |
| MACD | 0.09 | -0.15 |
| Stochastic Oscillator | 54.64 | 57.36 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.